Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA List Of Potential Safety Signals Has 3 Pfizer Drugs, Echoes Drug Watch Site

Executive Summary

FDA's quarterly report that lists potential signals of serious risks for drugs is similar in design to a program that the agency proposed and then withdrew following industry criticism

Related Content

CBER's Quarterly Safety Review Procedures Less Centralized Than CDER's
Additional Risks Of I.V. Anticonvulsants To Be Taken Up By FDA Panel
Drug Safety Should Focus On “Maximizing Benefit,” Not Just “Minimizing Risk” – FDA’s Goodman
Abilify Potential Safety Issues Flagged By FDA In Quarterly AERS Review
FDA Track Record In Risk Communication Raised As Key Sentinel Concern
Pfizer’s Drug Safety Web Site Aims To Reclaim Risk Communication Authority
Adverse Event Reporting Soars As Consumer Submissions Pass Physicians
FDA To Continue Providing Emerging Safety Info, But Not Through Drug Watch
Drug Safety Concerns Could Affect Early Review Stages, FDA's Gottlieb Says
FDA “Drug Watch” Early Warnings Will Have Lasting Negative Effect, PhRMA Says



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts